BioSpace News Archive

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that preclinical data from its ROR1-targeting cell therapy programs will be highlighted in a poster presentation at the European Hematology Association (EHA) 2022 Hybrid Congress.

NLS Pharmaceutics Ltd. announces that it has received a written notice from Nasdaq Stock Market LLC, indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Listing Rule 5550, which requires listed securities to maintain a minimum bid price of $1.00 per share.

CANbridge Pharmaceuticals Inc. announced that results from its CAN106 Phase 1 trial were presented at the 2022 European Hematology Association Congress, in Vienna, Austria, on June 10th.

Mirum Pharmaceuticals, Inc. announced that on June 10, 2022, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 43,550 shares of common stock and 21,800 restricted stock units to 8 new employees under Mirum’s 2020 Inducement Plan.

RemSleep Holdings Inc, a medical device manufacturer dedicated to forever changing the level of treatment provided to obstructive sleep apnea patients, announced that the company has officially filed its application for OTCQB® status with otcmarkets.com.

Abivax SA held its ordinary annual and extraordinary general meeting of shareholders on June 9, 2022, which was chaired by Prof. Hartmut Ehrlich, M.D., CEO of Abivax, in the absence of the Chairman of the Board of directors.

Ratio Therapeutics Inc. today announced its launch with a mission to develop best-in-class targeted radiopharmaceuticals for the treatment of cancers.

Disc Medicine, today presented the results from its phase 1 clinical study of DISC-0974, a first-in-class, monoclonal antibody designed to suppress hepcidin production by inhibiting hemojuvelin (HJV), at the European Hematology Association (EHA) Congress being held in Vienna, Austria.

EpiVax, Inc. (“EpiVax”) announces that it has developed VennVax, a smallpox vaccine candidate that is predicted to be highly effective against monkeypox.

Fulcrum Therapeutics, Inc. announced that the Company granted nonstatutory stock options to new employees as inducement awards outside of the Company’s 2019 Stock Incentive Plan.